Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (6)

2024

  1. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

    The Lancet, Vol. 404, Núm. 10459, pp. 1227-1239

2017

  1. Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44] (S0959804917300850) (10.1016/j.ejca.2017.01.024))

    European Journal of Cancer

  2. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

    European Journal of Cancer, Vol. 76, pp. 36-44

2014

  1. Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer

    Clinical Cancer Research, Vol. 20, Núm. 11, pp. 3012-3022

2013

  1. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A subgroup analysis of the phase III RADIANT-2 study

    Oncologist, Vol. 18, Núm. 1, pp. 46-53

  2. Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

    Clinical Cancer Research, Vol. 19, Núm. 5, pp. 1257-1268